Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The USFDA has issued 5 observations pursuant to the completion of audit
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Global Phase-3 study initiation expected in the second half of 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Sun Pharma's Dadra facility receives OAI status from US FDA
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
